# CIVIC Assertion6 (AID6) record, along with one of its six Evidence Lines - https://civicdb.org/events/assertions/6/summary
# This example does not use Propositions to capture Assertion semantics, and the evaluated target of Evidence Lines
# Assertion states that "EGFR L858R (somatic) predicts sensitivity to Afatinib treatment of NSCLC".

## ASSERTION
  - id: civic-data:AID6
    type: TherapeuticResponseStatement 
    description: "EGFR L858R positive NSCLC is sensitive to afatinib."     
    subject: civic-data:33                    # EGFR L858R. This will ultimately be a VRS object / descriptor. 
    predicate: predicts_sensitivity_to  
    object:
      - id: civic-data:drug_146               # The set of 'Drugs' comprising the treatment. To Do: Add TherInterv object    
        type: TherapeuticIntervention   
        label: Afatinib 
    allele_origin_qualifier:                      
      - id: GENO:0000882 
        label: somatic allele origin
    treated_condition_qualifier:              # The 'disease' context in which the treatment is given. To Do: Add GenCond object
      - id: civic-data:disease_8
        type: GeneticCondition   
        disease:            
          - DOID:3908    
            label: Lung Non-small Cell Carcinoma
            url: "http://www.disease-ontology.org/?id=DOID:3908   
    has_evidence_line: [civic-data:EID879, . . . ]     # Only one of the six evidence lines is shown here  
    was_specified_by: [civic-data:method_1, civic-data:method_2] 
    confidence_level: Tier I - Level A            # AMp-ASCO tier assigned to the ssertion by the curator
    qualified_contributions: [civic-data:Contribution001, civic-data:Contribution002, ... ]  # To Do, add Contribution objects
 


# EVIDENCE LINE
  - id: civic-data:EID879    
    type: EvidenceLine       
    evidence_direction:               # The evidence direction  assigned by the CIViC curator 
      - id: civic-term:002           
        label: supports
    evidence_strength:                # The evidence level code assigned by the CIViC curator
      - id: civic-term:001   
        label: B
    has_evidence_item:  civic-data:EvItem001              # the Evidence Item (Study Result0 that is evaluated as evidence
    qualified_contributions: [civic-data:Contribution101, civic-data:Contribution102, ... ]  # To Do, add Contribution objects



# EVIDENCE ITEM  (a StudyResult object)
  - id: civic-data:EvItem001  
    type: StudyResult         
    focus: civic-data:33      
    description: "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."
    confidence_level:                # The 'evidence/trust rating' assigned by the CIViC curtor
      - id: civic-term:003 
        label: 4-star
    reference: civic-source:592      # The publication that reported the result
          
           
# PUBLICATION (the source of data used as evidence)   # Current VA-SEPIO mdoel of Publications is minimal.   
  - id: civic-data:592 
    type: Publication   
    identifier:            
      - value: 25923549 
        system: PMID          
    label: "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
    url: "http://www.ncbi.nlm.nih.gov/pubmed/23816960"   


# METHODS
  - id: civic-data:method_1         
    type: VariantInterpretationGuideline
    label: Non-Small Cell Lung Cancer (v3.2018) 

  - id: civic-data:Method_2 
    type: EvidenceLevelGuideline
    label: AMP-ASCO-CAP Guidelines
    reference: PMID: 27993330


##------------------------------------------------------------------------------------------------------##

# CIVIC Assertion6 (AID6) record, along with one of its six Evidence Lines - https://civicdb.org/events/assertions/6/summary
# This example uses Propositions to capture Assertion semantics, and the evaluated target of Evidence Lines
# Assertion states that "EGFR L858R (somatic) predicts sensitivity to Afatinib treatment of NSCLC".

  - id: civic-data:AID6
    type: TherapeuticResponseStatement 
    description: "EGFR L858R positive NSCLC is sensitive to afatinib."     
    asserted_proposition: civic-data:Proposition001
    has_evidence_line: civic-data:EID879  
    was_specified_by: [civic-data:method_1, civic-data:method_2] 
    confidence_level: Tier I - Level A 
    qualified_contributions: [civic-data:Contribution001, civic-data:Contribution002, ... ]  # To Do  
 
# ASSERTED PROPOSITION (the claim that is put forth as true in Assertion AID6)
  - id: civic-data:Proposition001
    type: TherapeuticResponseProposition          # A specialization of VA-SEPIO 'Proposition'
    subject: civic-data:33                        # EGFR L858R. This will ultimately be a VRS object / descriptor. 
    predicate: predicts_sensitivity_to  
    object:
      - id: civic-data:drug_146                   
        type: TherapeuticIntervention   
        label: Afatinib 
    allele_origin_qualifier: 
      - id: GENO:0000882 
        label: somatic allele origin
    treated_condition_qualifier:
      - id: civic-data:disease_8
        type: GeneticCondition   
        disease:            
          - DOID:3908    
            label: Lung Non-small Cell Carcinoma
            url: "http://www.disease-ontology.org/?id=DOID:3908   

# EVIDENCE LINE
  - id: civic-data:EID879    
    type: EvidenceLine       
    evaluated_proposition: civic-data:Proposition002      # the Proposition against which the evidence is evaluated
    evidence_direction:      
      - id: civic-term:002   
        label: supports
    evidence_strength:  
      - id: civic-term:001   
        label: B
    has_evidence_item:  civic-data:EvItem001              # the Evidence Item / Study Result that is evaluated as evidence
    qualified_contributions: [civic-data:Contribution101, civic-data:Contribution102, ... ]  # To Do 

 
# EVALUATED PROPOSITION (the 'possible fact' that evidence was evaluated against to generate the Evidence Line)
  - id: civic-data:Proposition002           # NOTE this is DIFFERENT from the asserted Proposition in the root Assertion (disease is more specific)
     type: TherapeuticResponseProposition   
     subject: civic-data:33                 
     predicate:
       - id: ex:001                        
         label: predicts_sensitivity_to
     object:
       - id: civic-data:146
         type: TherapeuticIntervention      
         label: Afatinib 
     treated_condition_qualifier:
       - id: civic-data:30
         type: GeneticCondition           
         disease:        # The disease here is a descendent of disease int he asserted Proposition (Lung Non-small Cell Carcinoma)
           - DOID:3910
             label: Lung Adenocarcinoma
         url: "http://www.disease-ontology.org/?id=DOID:3910
     allele_origin_qualifier: 
       - id: GENO:0000882 
         label: somatic allele origin


# EVIDENCE ITEM  (a StudyResult object)
  - id: civic-data:EvItem001  
    type: StudyResult         
    focus: civic-data:33      
    description: "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."
    confidence_level: 
      - id: civic-term:003 
        label: 4-star
    reference: civic-source:592   
          
           
# PUBLICATION (the source of data used as evidence)    
  - id: civic-data:592 
    type: Publication   
    identifier:            
      - value: 25923549 
        system: PMID          
    label: "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
    url: "http://www.ncbi.nlm.nih.gov/pubmed/23816960"   


# METHODS
  - id: civic-data:method_1         
    type: VariantInterpretationGuideline
    label: Non-Small Cell Lung Cancer (v3.2018) 

  - id: civic-data:Method_2 
    type: EvidenceLevelGuideline
    label: AMP-ASCO-CAP Guidelines
    reference: PMID: 27993330


